EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers

Matthew Dankner iD, Emmanuelle Rousselle iD, Sarah Petrecca iD, François Fabi iD, Alexander Nowakowski iD, Anna-Maria Lazaratos iD, Charles Vincent Rajadurai iD, Andrew J B Stein, David Bian, Peter Tai, Alicia Belaiche iD, Meredith Li und 7 weitere

JCO Precision Oncology · 2025-01 · (9)

DOI: 10.1200/po.24.00199 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift JCO Precision Oncology, 2025-01. Verfasst von Matthew Dankner und 18 weiteren Autor:innen. Beteiligte Einrichtung: McGill University Faculty of Medicine, Montréal, QC, Canada. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Neoplasms, MAP Kinase Kinase 1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE MAP2K1/MEK1 mutations are potentially actionable drivers in cancer. MAP2K1 mutations have been functionally classified into three groups according to their dependency on upstream RAS/RAF signaling. However, the clinical efficacy of mitogen-activated protein kinase (MAPK) pathway inhibitors (MAPKi) for MAP2K1-mutant tumors is not well defined. We sought to characterize the genomic and clinical landscape of MAP2K1 mutant tumors to evaluate the relationship between MAP2K1 mutation class and clinical activity of MAPKi. METHODS We interrogated American Association for Cancer Research (AACR) GENIE (v13) to analyze solid tumors with MAP2K1 mutations. We performed a systematic review and meta-analysis of published reports of patients with MAP2K1-mutant cancers treated with MAPKi according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The primary end point was progression-free survival (PFS), and secondary end points were overall treatment response rate (ORR), duration of response (DOR), and overall survival. RESULTS In the AACR GENIE data set, class 2 MAP2K1 mutations (63%) were more prevalent than class 1 (24%) and class 3 (13%) mutations ( P < .0001). Co-occurring MAPK pathway-activating mutations were more likely to occur in class 1 versus class 2 or 3 MAP2K1-mutant tumors ( P < .0001). Our systematic meta-analysis of the literature identified 46 patients with MAP2K1-mutant tumors who received MAPKi. In these patients, ORR was 28% and median PFS was 3.9 months. ORR did not differ according to MAP2K1 mutation class or cancer type. However, patients with class 2 mutations experienced longer PFS (5.0 months) and DOR (23.8 months) compared with patients with class 1, 3, or unclassified MAP2K1 mutations (PFS 3.5 months, P = .04; DOR 4.2 months, P = .02). CONCLUSION Patients with class 2 MAP2K1 mutations represent a novel subgroup that may derive benefit from MAPKi. Prospective clinical studies with novel MAPKi regimens are warranted in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsNeoplasmsMAP Kinase Kinase 1HumansMutationNeoplasm Metastasis

Substanzen

Protein Kinase InhibitorsMAP2K1 protein, humanMAP Kinase Kinase 1

Autor:innen und Institutionen

  • McGill University Faculty of Medicine, Montréal, QC, Canada.
  • Lady Davis Research Institute & Segal Cancer Centre, Jewish General Hospital, Montréal, QC, Canada.
  • Rosalind and Morris Goodman Cancer Institute, Montréal, QC, Canada.
  • Division of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, QC, Canada.
  • Schulich Library of Physical Sciences, Life Sciences, and Engineering, McGill University, Montréal, QC, Canada.
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), Italy.

ORCID-Profile: Matthew Dankner, Emmanuelle Rousselle, Sarah Petrecca, François Fabi, Alexander Nowakowski, Anna-Maria Lazaratos, Charles Vincent Rajadurai, Alicia Belaiche, Andrea Quaiattini, Nicola Normanno, Arielle Elkrief, Douglas B Johnson, Marc Ladanyi, April A N Rose

Förderung

  • NCI NIH HHS

Zitieren

APA

Dankner, M., Rousselle, E., Petrecca, S., Fabi, F., Nowakowski, A., Lazaratos, A. M., Rajadurai, C. V., Stein, A. J. B., Bian, D., Tai, P., Belaiche, A., Li, M., Quaiattini, A., Normanno, N., Arcila, M., Elkrief, A., Johnson, D. B., Ladanyi, M., & Rose, A. A. N. (2025). Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers. JCO Precision Oncology. https://doi.org/10.1200/po.24.00199

Vancouver

Dankner M, Rousselle E, Petrecca S, Fabi F, Nowakowski A, Lazaratos AM, et al. Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers. JCO Precision Oncology. 2025. doi:10.1200/po.24.00199

BibTeX
@article{Dankner2025,
  author = {Dankner, Matthew and Rousselle, Emmanuelle and Petrecca, Sarah and Fabi, François and Nowakowski, Alexander and Lazaratos, Anna-Maria and Rajadurai, Charles Vincent and Stein, Andrew J B and Bian, David and Tai, Peter and Belaiche, Alicia and Li, Meredith and Quaiattini, Andrea and Normanno, Nicola and Arcila, Maria and Elkrief, Arielle and Johnson, Douglas B and Ladanyi, Marc and Rose, April A N},
  title = {Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po.24.00199}
}
Kostenlos starten →